Prostate-specific Antigen Nadir and Cancer-Control Outcomes in Real-world Apalutamide-treated Metastatic Hormone-Sensitive Prostate Cancer Patients: A Single-Center Analysis
A prostate-specific antigen (PSA) nadir of <0.02 ng/ml and PSA responses ≥99% are associated with better cancer-control outcomes in metastatic hormone-sensitive prostate cancer patients treated with apalutamide.
Authors
- Felix K.‐H. Chun (ORCID: https://orcid.org/0000-0001-8486-9536)
- Axel S. Merseburger (ORCID: https://orcid.org/0000-0001-6467-3931)
- Luis A. Kluth (ORCID: https://orcid.org/0000-0002-4629-4388)
- Derya Tilki (ORCID: https://orcid.org/0000-0001-7033-1380)
- Clara Humke
- Philipp Mandel (ORCID: https://orcid.org/0000-0002-0760-7281)
- Mike Wenzel (ORCID: https://orcid.org/0000-0002-4338-0889)
- Thomas Steuber
- Benedikt Hoeh (ORCID: https://orcid.org/0000-0002-4238-6584)
- Cristiana Cano Garcia
Institutions
- Goethe University Frankfurt (DE)
- Universität Hamburg (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- Martini-Klinik (DE)
- University Hospital Schleswig-Holstein (DE)
- University Hospital Frankfurt (DE)
- University of Lübeck (DE)
Publication Details
- Journal
- European Urology Oncology
- Published
- 2024-08-31
- DOI
- https://doi.org/10.1016/j.euo.2024.08.007
- Citations
- 15
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 6.28